Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Free Report) have been assigned an average recommendation of “Buy” from the six research firms that are covering the company, MarketBeat reports. Six research analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have covered the stock in the […]
Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Free Report) CAO Patricia Carr sold 158 shares of the firm’s stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $138.16, for a total value of $21,829.28. Following the completion of the sale, the chief accounting officer now owns […]
Archer Investment Corp lifted its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) by 8,333.3% during the first quarter, Holdings Channel reports. The firm owned 506 shares of the specialty pharmaceutical company’s stock after buying an additional 500 shares during the period. Archer Investment Corp’s holdings in Jazz Pharmaceuticals were worth $70,000 […]
Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) had its price objective raised by Bank of America from $204.00 to $217.00 in a research note published on Thursday morning, Marketbeat Ratings reports. The firm currently has a buy rating on the specialty pharmaceutical company’s stock. A number of other analysts also recently issued reports on JAZZ. StockNews.com […]
Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) by 16.1% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 22,385 shares of the specialty pharmaceutical company’s stock after purchasing an additional 3,103 shares during the […]